| |
Patients with PsA (N = 442)
|
|---|
| | | |
Prior TNF antagonist(s)
|
Reason for discontinuation of prior TNF antagonista
|
|---|
| |
No prior ETN/IFX
|
Prior ETN and/or IFX
|
IFX only
|
ETN only
|
IFX and ETN
|
Lack of response
|
Loss of response
|
Intolerance
|
|---|
|
Characteristic
|
(n = 376)
|
(n = 66)
|
(n = 18)
|
(n = 34)
|
(n = 14)
|
(n = 14)
|
(n = 29)
|
(n = 9)
|
|---|
|
Male (%)
|
50
|
47
|
61
|
41
|
43
|
50
|
45
|
44
|
|
Age (years; mean ± SD)
|
48 ± 11
|
47 ± 12
|
44 ± 12
|
47 ± 13
|
50 ± 8
|
43 ± 10
|
48 ± 13
|
51 ± 11
|
|
PsA duration (years; mean ± SD)
|
10 ± 8
|
12 ± 8
|
13 ± 7
|
9 ± 8
|
17 ± 8
|
7 ± 5
|
14 ± 7
|
14 ± 11
|
|
Psoriasis (%)b
|
83
|
80
|
78
|
79
|
86
|
79
|
79
|
78
|
|
Nail dystrophy (%)c
|
59
|
55
|
72
|
41
|
64
|
43
|
62
|
11
|
|
Concomitant DMARDs (%)
|
71
|
52
|
72
|
35
|
64
|
29
|
59
|
44
|
|
Concomitant glucocorticoids (%)
|
26
|
44
|
44
|
41
|
50
|
36
|
41
|
44
|
|
C-reactive protein (mg/dl)d
|
0.9
|
1.3
|
0.8
|
1.5
|
1.1
|
0.8
|
1.6
|
1.4
|
| |
0.4, 2.2
|
0.3, 2.8
|
0.1 to 8.4e
|
0.1 to 7.0e
|
0.5 to 4.7e
|
0.1 to 7.0e
|
0.1 to 8.4e
|
0.2 to 3.4e
|
- aNo additional reason except for "other." bPatients with PGA other than "Clear." cPatients with NAPSI score ≥ 1. dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. eRanges presented are minimum to maximum because of small numbers of patients per group. DMARDs, disease-modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; NAPSI, nail psoriasis severity index; NSAID, nonsteroidal antiinflammatory drug; PGA, Physician's Global Assessment of psoriasis; PsA, psoriatic arthritis; TNF, tumor necrosis factor.
